Adam James, PharmD, is manager of immunization and clinical programs at Rite Aid, as well as other clinical programs such as preexposure/postexposure prophylaxis and travel health.
Panelists discuss clinical strategies to improve RSV vaccine uptake in high-risk adults by reviewing disease severity, comparing approved vaccines, and emphasizing the pharmacist’s pivotal role in patient education and vaccine advocacy to overcome hesitancy and increase protection in vulnerable populations.
A panelist discusses key insights for pharmacists to prioritize, including staying informed about new respiratory syncytial virus (RSV) vaccines such as Arexvy and Abrysvo, educating patients on the benefits of vaccination, monitoring common adverse effects, ensuring timely access to vaccines, and playing a crucial role in supporting patient safety and prevention efforts for RSV.
A panelist discusses recent advancements in the respiratory syncytial virus (RSV) vaccine space, including the approval of Arexvy and Abrysvo for older adults and pregnant individuals, the development of promising mRNA and protein subunit vaccines for high-risk groups, and ongoing studies to optimize dosing schedules and booster needs, all aimed at reducing RSV-related hospitalizations and deaths.
A panelist discusses how physicians can support pharmacists in monitoring respiratory syncytial virus (RSV) vaccine adverse events (AEs), such as soreness, fatigue, and headache, while using clear, empathetic communication to educate patients about the temporary nature of these symptoms and the significant benefits of preventing severe RSV illness.
A panelist discusses how physicians can collaborate with pharmacists to share patient information, coordinate vaccine schedules, and reinforce recommendations, while utilizing resources such as CDC guidelines, patient brochures, and digital tools to provide clear, evidence-based education on RSV prevention and vaccination.
A panelist discusses how physicians can collaborate with community pharmacists to enhance respiratory syncytial virus (RSV) vaccine uptake by leveraging pharmacists' expertise in patient education, addressing vaccine hesitancy through empathetic communication, and emphasizing the safety, benefits, and risks of RSV vaccination.
A panelist discusses how physicians can navigate respiratory syncytial virus (RSV) vaccine selection by considering patient age, pregnancy status, and seasonality, highlighting the approved indications for Arexvy and Abrysvo, including maternal immunization to protect infants through passive immunity.
A panelist discusses how physicians can partner with pharmacists to identify respiratory syncytial virus (RSV) vaccine candidates among high-risk populations, emphasizing the pharmacist’s role in prevention efforts and the importance of supportive care and awareness of newly approved vaccines and monoclonal antibodies.
A panelist discusses how physicians can recognize the burden of RSV in high-risk populations, stay informed about preventive strategies such as vaccines and monoclonal antibodies, and apply clinical insights to reduce severe outcomes and hospitalizations.
Many patients may struggle to understand the complex immunization schedules compiled by the CDC.
Patient education on the risks of the long-term illness can help overcome vaccine hesitancy.
Embracing artificial intelligence and other tools will be necessary to push the field forward.
New ACIP recommendations provide clarity, but questions linger for those aged 60 to 74 years.
As Summer Approaches, Many Will Be Planning Vacations and Trips Abroad
Sharing data and a personal recommendation can make a difference in a patient’s life
